✦ LIBER ✦

5-HT3receptor antagonistsvstraditional agents for the prophylaxis of postoperative nausea and vomiting

✍ Scribed by Peter S. Loewen; Carlo A. Marra; Peter J. Zed

Publisher: Springer-Verlag
Year: 2000
Tongue: French
Weight: 131 KB
Volume: 47
Category: Article
ISSN: 1496-8975
DOI: 10.1007/bf03024875

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

GR38032F, a 5HT3receptor antagonist, in

GR38032F, a 5HT3receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

✍ Michel Marty; Jean P. Droz; Pierre Pouillart; Bernard Paule; Nils Brion; Jacques 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 330 KB

A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/ m 2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting. GR38032F, a 5HT3 receptor antagonist, was given 30 min prior to cisplatin as

Anticipatory nausea and vomiting in the

Anticipatory nausea and vomiting in the era of 5-HT3antiemetics

✍ G. R. Morrow; Joseph A. Roscoe; Jeffrey J. Kirshner; Harry E. Hynes; Richard J. 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 30 KB

Premedication with H1and H2blocking agen

Premedication with H1and H2blocking agents reduces the incidence of postoperative nausea and vomiting

✍ A. W. Doenicke; R. Hoernecke; I. Celik 📂 Article 📅 2004 🏛 SP Birkhäuser Verlag Basel 🌐 English ⚖ 132 KB

A phase I study of a new 5HT3-receptor a

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

✍ Geoffrey Falkson; Adriaan J. Zyl 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 370 KB

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experien

RETRACTED ARTICLE: Current prevention an

RETRACTED ARTICLE: Current prevention and treatment of postoperative nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists: a review

✍ Yoshitaka Fujii; Hidenori Toyooka 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 73 KB

High versus low dose granisetron, a sele

High versus low dose granisetron, a selective 5HT3antagonist, for the prevention of chemotherapy-induced nausea and vomiting

✍ H. C. Falkson; C. I. Falkson; G. Falkson 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 173 KB

Fifty six patients, with histologically confirmed cancer, who received highly emetogenic chemotherapy, were entered on a randomized double blind, low versus high dose, study of granisetron, a 5HT3 receptor antagonist. A single dose of intravenous granisetron protected the majority of patients from n